ISTH 2021 Congress Archives - ISTH Congress Abstracts

Abstract Number: PB1261

Tailored Anticoagulant Treatment after a First Venous Thromboembolism: Protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) Study, a Cohort Based Randomized Controlled Trial

J.L.I. Burggraaf¹, N. van Rein¹, R.H.H. Bemelmans², S. Benimadho³, J.W.K. van den Berg⁴, M. Coppens⁵, A. Dees⁶, L.M. Faber⁷, W.K. de Jong⁸, T. Koster⁹, A.T.A. Mairuhu¹⁰, K. Meijer¹¹, M. Nijkeuter¹², M.E. van den Akker - van Marle¹³, S. le Cessie^13,1, M.V. Huisman¹⁴, F.A. Klok¹⁴, S.C. Cannegieter^1,14, L-TRRiP study investigators
Abstract Number: PB0676

Tailoring the Effect of Antithrombin-targeting Therapy in Hemophilia A Using in Silico Thrombin Generation

R. de Laat-Kremers¹, M. Ninivaggi¹, I. van Moort², M. de Maat², B. de Laat¹
Abstract Number: PB0656

Targeted CRISPR/Cas9-mediated Gene Addition to a Safe Harbor in Placental Cells for the Treatment of Hemophilia A

R.M. Ramamurthy¹, M. Rodriguez¹, D. Meares², A. Farland², A. Atala¹, C.B. Doering³, H.T. Spencer³, C.D. Porada¹, G. Almeida-Porada¹
Abstract Number: PB0869

Targeted Next Generation Sequencing for the Diagnosis of Patients with Inherited Thrombocytopenias

O. Gilad¹, O. Steinberg - Shemer¹, O. Dgany², T. Krasnov², S. Noy - Lotan², J. Yacobovich¹, H. Tamary^2,1
Abstract Number: PB1032

Targeted Proteasomal Degradation of Platelet BTK and TEC as a Novel Approach in Thrombosis Prevention

A. Munkacsi¹, K. Sledz¹, I. Hers¹
Abstract Number: OC 36.4

Targeted Protein Biomarker Discovery to Predict Cardiovascular Outcome in Peripheral Artery Disease

B. Kremers¹, J. Posma¹, S. Heitmeier², H. ten Cate^1,3, A. ten Cate-Hoek^1,3, R. van Oerle¹, J.-W. Daemen³, B. Mees³, H. Spronk¹
Abstract Number: OC 60.3

Targeting Coagulation Factor Xa and IIa Differentially Regulate Inflammation

K. Shahzad¹, I. Gadi¹, S. Fatima¹, A. Elwakiel¹, B. Isermann¹
Abstract Number: PB1037

Targeting Pathways of Mitochondrial Neutrophil Extracellular Trap Formation to Inhibit Progression of Abdominal Aortic Aneurysms in Preclinical Models

S. Bleichert¹, N. Ibrahim¹, J. Klopf¹, V. Knöbl¹, A. Busch², M. Bailey³, W. Eilenberg¹, C. Neumayer¹, C. Brostjan¹
Abstract Number: PB0148

Targeting Thymidine Phosphorylase May Be a Novel Therapy for COVID-19

H. Yue¹, K. Denning¹, W. Li¹
Abstract Number: PB0199

TEG/ROTEM: A Tool to Aid in the Diagnosis and Management of COVID 19 Coagulopathies – A Systematic Review

S. Kazi¹, A. Noureldin², K. Fainchtein², Y. Deng², M. Othman^2,3
Abstract Number: PB0597

Telemedicine in Hemophilia: A Comprehensive Review

C.L Li¹, K. Strike^2,3, D. Matino^2,4, M. Bhatt^1,2, K. Decker², A.K. Chan^1,2
Abstract Number: LPB0083

Temporal Assessment of Platelet Proteome and fFnction during ex vivo Anticoagulation

S. Tassi Yunga¹, A. Gowers¹, A. Melrose¹, M. Fitzgerald¹, A. Rajendran¹, A. Reddy¹, P. Wilmarth¹, L. David¹, O. McCarty¹, J. Aslan¹
Abstract Number: PO159

Tetralogy of Fallot with Thrombolytic Ongoing Processes: A Case Report

B. Badlou¹, H. Najafpour².
Abstract Number: OC 58.1

The “Double-edged Sword”: The Role of LMWPTP in Platelet Hyperactivity in Cancer Patients

A.V.S. Faria^1,2, B. Yu², S.S. Andrade³, M. Peppelenbosch², G. Fuhler², C.V. Ferreira-Halder¹
Abstract Number: PB1278

The Accelerated Regimen of Low Dose Recombinant Tissue-type Plasminogen for the Treatment of Acute Pulmonary Embolism: A Case Series from Vietnam

B.H. Hoang¹, G.P. Do², D.L. Le³, T.H.T. Bui⁴, N.T. Bui⁵, M.Q. Nguyen³, D.A. Nguyen⁴, M.M Dinh⁶, L.H. Nguyen¹
Abstract Number: PB0875

The Analysis of Platelet Functional Activity in Patients with Thrombocytopenia

M. Reshetova¹, A. Poletaev¹, E. Seregina^1,2, D. Polokhov¹
Abstract Number: PB0293

The Assessment of Thrombotic Complication in Patients with COVID-19

V.M. Popov¹, M. ANDREESCU¹, M. OMER¹, M. Popescu¹, C. Despan¹, L. Iliescu¹, C. Pirvu¹, A. Grigorie¹, M. Niculae¹, O. Constantin¹, A. Rus¹, A. Badea¹, I. Simion¹, M.I. Balea¹
Abstract Number: PB1126

The Association among von Willebrand Factor, ADAMTS-13, D-dimer, and Soluble P-selectin with Venous Thromboembolism Incidence in Cancer Patients: Systematic Review and Meta-analysis

B.P. Putra¹, F.N. Putra²
Abstract Number: LPB0117

The Association of Emicizumab and rFVIIa for Major Orthopaedic Surgery

C. Carulli¹, S. Linari², L. Pieri², G. Castaman²
Abstract Number: PB0794

The Bacteria-associated Thrombosis, Thrombophlebitis and LEmierre Syndrome (BATTLE) Registry: Background and Rationale

L. Valerio¹, G. Corsi², T. Sebastian³, S. Barco³
Abstract Number: PO142

The Case of Acquired Haemophilia A

O. Stasyshyn¹, V. Krasivska¹
Abstract Number: PO191

The Case of Obstetric APS – A Therapeutic Challenge

J. Teliga-Czajkowska¹, K. Czajkowski², A. Sikorska³
Abstract Number: PB0229

The Characteristics and Outcomes of Critically Ill Patients with COVID-19 who Received Systemic Thrombolysis for Presumed Pulmonary Embolism: An Observational Study

M. So¹, D. Steiger¹, M. Takahashi¹, N. Egorova², T. Kuno¹.
Abstract Number: PB0548

The Clinical Bleeding Phenotype of Patients with Non-severe Hemophilia A and B

A. Zwagemaker¹, F. Kloosterman¹, M. Coppens², C.N. Bagot³, E.A.M. Beckers⁴, S. Boyce⁵, P. Brons⁶, M.H. Cnossen⁷, J. Eikenboom⁸, F.W.G. Leebeek⁹, C. Male¹⁰, K. Meijer¹¹, L. Nieuwenhuizen¹², S.C. Gouw^1,13, J.G. van der Bom¹⁴, G. Castaman¹⁵, K. Fijnvandraat^1,16, DYNAMO Study Group
Abstract Number: PB0843

The Clinical Burden of Congenital and Immune-mediated Thrombotic Thrombocytopenic Purpura: A Retrospective Cohort Analysis

A. Satija¹, S. Tzivelekis², E. Swallow¹, O. Patterson-Lomba¹, A. Briggs¹, E. Yim¹, B. Mellgard³
Abstract Number: PB0013

The Coagulation and Fibrinolisys Changes Undergoing the Ramipril and Losartan Treatment of Concomitant Arterial Hypertension and Diabetes Mellitus Type 2

E. Shorikov¹, D. Shorikova¹, P. Shorikov¹, O. Khukhlina¹
Abstract Number: PB0065

The Coagulation Balance: Intracranial Hemorrhage in a Patient with Antithrombin Deficiency. A Case Report

I. Machado¹, S. Teixeira¹, D. Cibele Gonçalves¹, C. Monteiro¹, M. Carvalho¹, L. Ricca Gonçalves¹, C. Neves¹, M.d.C. Koch¹
Abstract Number: PB0240

The Comparison of Different Coagulation Markers in Thrombosis Prediction in COVID-19 Pneumonia

M. Krykhtina¹, K. Bielosludtseva¹, T. Pertseva¹, L. Konopkina¹
Abstract Number: PB0285

The Comparison of ISTH Criteria for Disseminated Intravascular Coagulation (DIC) Scale, Padua Scale, D-dimer and Fibrinogen Like the Best Predictor of Thrombosis in COVID-19 Pneumonia

K. Bielosludtseva¹, T. Pertseva¹, L. Konopkina¹, M. Krykhtina¹
Abstract Number: PB0866

The Copenhagen Founder Variant GP1BA c.58T>G is Causal of Monoallelic Bernard-Soulier Syndrome

E. Leinøe¹, N. Broens¹, A.O. Rasmussen², M. Gabrielaite², S. Rosthoej³, E. Zetterberg⁴, S.R. Ostrowski⁵, M. Rossing²
Abstract Number: PB0814

The Correlation of Vascular Platelet Hemostasis Disorders and Typical Autoantibodies in Hepatic Cirrhosis at the Outcome of Autoimmune Hepatitis in Children

E. Konovalova¹, A. Lavrova¹, M. Presniakova¹
Abstract Number: NUR 01.4

The DATCH Project: Developmentally Appropriate Tools for Children with Hemophilia to Help Them Better Understand Their Disease

C.L Li¹, N. Seroski², A. Sohanlal^1,3, K. Strike^4,5, R. Goldsmith⁵, K. Decker⁵, A.K. Chan^1,2,5
Abstract Number: PO149

The Detection of Hemophilia C in a 66-year-Old Patient with Postoperative Urinary Bleeding

I. Melnichenko^1,2, T. Arakelyan¹, N. Sargsyan^2,3, L. Sargsyan^1,2, S. Danielyan⁴, G. Tamamyan^1,2, H. Khachatryan^2,3
Abstract Number: PB0558

The Devil is in the Detail: An Irish Approach to Switching to Emicizumab Prophylaxis in an Adult Comprehensive Care Centre (CCC)

E. Singleton¹, N. Larkin¹, M. Mc Gowan¹, S. Roche¹, C. Bergin¹, M. Byrne¹, K. Ryan¹, M. Lavin¹, J. O Donnell¹, N. O Connell¹
Abstract Number: PB1058

The Diagnostic Utility of the Taipan Snake Venom Time in an Era of DOACstop™

E. Foxton¹, R. Polgrean¹, M. Desborough², G. Ling²
Abstract Number: OC 22.2

The Difference in the Transglutaminase Activities of Proteolytically and Non-proteolytically Activated FXIII A is Dependent on the Substrates

R. Darul Amne Syed Mohammed¹, M. Maurer¹
Abstract Number: PB0780

The Distribution of Anti-platelet Membrane Glycoprotein Antibodies Subtypes in Children with Primary Immune Thrombocytopenia and its Relationship with Therapeutic Effect

R. Li¹, R. Yang¹
Abstract Number: PB0297

The Effect of Chronic Anticoagulation and Antiplatelets on COVID-19 Infection

J. Kaur¹, A. Abdou¹, M. Mohammed¹, Y. Nadeem¹, M. Kulkarni¹, P. Dixit¹, Q. Jehangir¹, A. Morani¹, Y. Lee¹, I. Mohamed¹, M. Qamar¹, P. Pulapati¹, J. Duong¹
Abstract Number: PB0277

The Effect of Covid-19 Lockdown on Patients Taking Warfarin

M. Roberts¹
Abstract Number: PB0060

The Effect of Dextran Sulfate in Heparin Monitoring Reagents

E. Dean¹
Abstract Number: PB1047

The Effect of DNase I in Combination with Unfractionated Heparin or Low Molecular Weight Heparin in a Mouse Model of Sepsis

S. Medeiros¹, N. Sharma¹, D. Dwivedi¹, S. Sohrabipour¹, V. De Sousa¹, J. Zhou¹, P.C Liaw¹
Abstract Number: PB0333

The Effect of DOAC Stop^TM on Measuring Antithrombin Activity

K. Mayger^1,2,3, N. De Jager¹, E. Foxton¹, A. Doyle², B.J. Hunt²
Abstract Number: PB0413

The Effect of Lower-leg Trauma and Knee Arthroscopy on the Natural Anticoagulant and Fibrinolytic Systems

C. Touw¹, B. Nemeth¹, R. van Adrichem¹, W. Lijfering¹, A. van Hylckama Vlieg¹, R. Nelissen¹, T. Lisman², S. Cannegieter¹
Abstract Number: PB0053

The Effect of Lower-leg Trauma and Knee Arthroscopy on Thrombin Generation

C.E. Touw¹, B. Nemeth¹, R. van Adrichem¹, W. Lijfering¹, A. van Hylckama Vlieg¹, R. Nelissen¹, T. Lisman², S. Cannegieter¹
Abstract Number: OC 20.3

The Effect of Platelets on Thrombin Generation in the Premature Infant: The EVENT Study

C. Murphy^1,2, E. Neary^3,4, B. Kevane⁵, D. O'Reilly², J. O'Loughlin⁶, A. EL-Khuffash^2,1, P. Maguire⁷, F. NíAinle^5,7,8,9, N. McCallion^2,1
Abstract Number: PB1314

The Effect of Prothrombin Complex Concentrate and Cryoprecipitate on the Frequency and Severity of Multiple Organ Dysfunction Syndrome in Massive Obstetric Haemorrhage

V. Sedinkin¹, O. Klygunenko¹, O. Volkov¹
Abstract Number: PB0674

The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood

M. Ezban¹, K. Jensen¹, J. Lund¹
Abstract Number: PB0360

The Effect of Trough Dabigatran Plasma Concentration on Rotational Thromboelastometry Parameters

M. Milić¹, J. Štanfel¹, K. Paradinović¹, V. Šerić¹
Abstract Number: PB0295

The Effects of COVID-19 Pandemic on Children with Haemophilia

F.B. Kurtipek¹, D. Gürlek Gökçebay¹, V. Çulha¹, N.Y. Özbek¹
Abstract Number: PB1004

The Effects of Iron Deficiency on Platelet Function, Indices, and Clinically Reported Hemostasis: A Prospective Clinical Study of Iron Deficient Women Receiving IV Iron

B. Elstrott¹, M. West², H.H.S. Lakshmanan³, J. Aslan³, J.J. Shatzel^2,3
Abstract Number: PB0520

The Efficacy and Prognosticator for Inhibitor Eradication in Hemophilia A Boys with High-titer Inhibitors Using a Low-dose Immune Tolerance Induction Strategy (with or without Immunosuppressants): Data from the National Center for Children’s Health of China

Z. Li¹, Z. Chen¹, G. Liu¹, X. Cheng¹, W. Yao¹, K. Huang¹, G. Li¹, Y. Zhen¹, X. Wu¹, S. Cai¹, M.-C. Poon², R. Wu¹
Abstract Number: PB1145

The Evaluation of the Children with Intracranial Thrombosis

A. Meral Güneş¹, S. Güler¹, Ö. Tüfekçi², M. Sezgin Evim¹, B. Baytan¹, Ş. Yılmaz², H. Ören²
Abstract Number: PB0445

The Experience of Oran University Hospital in Algeria in the Management of Acquired Hemophilia

R. Messaoudi¹, D.SAIDI, N.LAHMAR, D.BELALDJ, A.MOUADEN, M.BENSAHLI, M.DJAAFR,H.TOUHAMI
Abstract Number: LPB0039

The Extracellular Protease EpiP from S. aureus Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1

V. De Filippis¹, I. Artusi¹, G. Pontarollo², L. Acquasaliente¹, A. Pagotto¹, C.M. Radu³, F. Bagnoli⁴, G. Pietrocola⁵, P. Speziale⁵
Abstract Number: OC 41.2

The Factor XII-uPAR Axis Drives Ovarian Cancer Maintenance and Progression

K.L. Bane¹, J. McAnulty², A. Gandhi², S. Vatolin¹, Y. Yang³, M.J. Flick³, A. DiFeo^2,4,5, E.X. Stavrou^1,6
Abstract Number: LPB0016

The Fibrin(ogen) γ-chain Integrin αIIbβ3 Binding Motif is Dispensable for Platelet Accumulation but Modifies Cross-linking in the Injured Liver

L.G. Poole¹, D.J. Groeneveld¹, H.M. Cline-Fedewa¹, M.J. Flick², J.P. Luyendyk¹
Abstract Number: PB0588

The FⅨ Gene Mutation Analysis of Hemophilia B in China Central and Western Regions

W. Wang¹, L. Xu², J. Wu³, J. Jin⁴, J. Huang⁴, Q. Zhang⁵, M. Zhou⁵, Z. Xu⁶, Y. Huang⁶, J. Peng⁷, Q. Hu¹
Abstract Number: PB0039

The FV East Texas Variant Causes Bleeding in a Three Generation Family from Indiana

J. Peterson¹, S. Gupta², N. Martinez¹, A. Mast¹
Abstract Number: PB0893

The Glanzmann’s Thrombasthenia Registry (GTR): Safety of Platelet Therapy in Patients with Glanzmann’s Thrombasthenia, with a Focus on Changes in alloimmunization Status

M.-C. Poon^1,2, R. d’Oiron³, S. Baby⁴, R.B Zotz^5,6, G. Di Minno⁷
Abstract Number: PB0340

The Impact of Inactive FVIII Antigen in Factor VIII Deficient Plasma on the Measurement of FVIII Inhibitors

A. Wood¹, N. Kesavan¹, A. Sadeghi-Khomami,¹, K. Black¹, M. Boylan¹, R. Ni², J. Della Maestra², P. Erb², D. Foulon², H. Hoogendoorn²
Abstract Number: PB0056

The Impact of Lower-leg Injury and Knee Arthroscopy on Procoagulant Factor Levels

C.E. Touw¹, B. Nemeth¹, I. Schipper¹, R. Nelissen¹, S. Cannegieter¹
Abstract Number: PB0554

The Impact of PK-guided Prophylaxis on Clinical Outcomes and Resource Utilization in Hemophilia A Patients: Real-world Evidence From the CHESS II Study

E. Ferri Grazzi¹, T. Burke^1,2, J. O'Hara^1,2, S.X Sun³
Abstract Number: PB0651

The Impact of Platelet αIIbβ3 on the Hemostatic Efficacy of Platelet-derived FVIII Gene Therapy

H. Yu^1,2, J.A. Schroeder^1,2, J.G. Mattson², Q. Shi^1,2,3,4
Abstract Number: PB1078

The Impact of Strong Inducers on Direct Oral Anticoagulant Plasma Levels: A Retrospective Study

A.-L. Sennesael¹, A.-S. Larock¹, P. Hainaut², S. Lessire³, M. Hardy^3,4, J. Douxfils⁵, A. Spinewine^1,6, F. Mullier⁴
Abstract Number: LPB0046

The Impact of the ABO Blood Group on Postpartum Haemorrhage Risk among Women with Thrombocytopenia

S. Arcudi¹, A. Ronchi², M. Capecchi³, M.W. Ossola², I. Mancini¹, A.M. Marconi⁴, G. Podda⁵, A. Artoni⁶
Abstract Number: PB0772

The Importance of Follow up Post PE

M. Roberts¹
Abstract Number: PB0664

The Importance of Patient Preferences and Other Patient-Centric Metrics in Developing and Evaluating New Haemophilia Treatments

T. Burke^1,2, S. Asghar¹, J. O'Hara^1,2, D. Yee³, S. Kar³
Abstract Number: OC 52.1

The Importance of the GPIbα Intracellular Tail in VWF-mediated Platelet Signaling Events and Platelet/Neutrophil Interactions

A. Adela Constantinescu-Bercu¹, Y.A Wang¹, K.J Woollard¹, P. Mangin², K. Vanhoorelbeke³, J.T. Crawley¹, I.I Salles-Crawley¹
Abstract Number: LPB0060

The Incidence of Severe Infusion Reactions Associated with Common Iron Repletion Strategies

A. Arastu¹, J. Cohen², M. Oakes¹, S. Olson³, B. Elstrott¹, J. Aslan⁴, T. DeLoughery³, J. Shatzel³
Abstract Number: PB1292

The Influence of Thrombophilic Anamnesis and Thrombotic Complications Heredity

N. Vorobyeva^1,2, D. Gamyrkina²
Abstract Number: PB0768

The Intact Heavy Chain of Plasminogen Supresses Angiogenesis More Strongly than the Known Angiostatin

K. Gershkovich¹, L. Mukhametova², R. Aisina²
Abstract Number: OC 37.4

The Intracellular Tail of GPIbα Augments GPVI-mediated Signaling in Mice

A. Constantinescu-Bercu¹, Y.A Wang¹, K.J Woollard¹, P. Mangin², K. Vanhoorelbeke³, J.T. Crawley¹, I.I Salles-Crawley¹
Abstract Number: PB0167

The Kallikrein-kinin System in Bronchoalveolar Lavage Fluid from Patients with COVID-19

C.P. Martens^1,2, P. Van Mol^3,4, J. Wauters^5,6, E. Wauters⁷, T. Gangnus⁸, B. Noppen⁹, L. Liesenborghs^1,10, E. Heylen¹⁰, S. Jansen¹⁰, L.C. Velásquez Pereira¹, M.M Engelen^1,2, A. Van Herck⁷, R. Vos^7,4, C. Vandenbriele^1,2, K. Martinod¹, B.B Burckhardt⁸, M. Vanhove⁹, P. Verhamme^1,2, J. Neyts¹⁰, T. Vanassche^1,2
Abstract Number: OC 12.1

The Khorana Score Is a Marker of Poor Cancer Prognosis, Independent of Development of VTE

G. Soff¹, C. Sathe², C. Poon¹, S. Yin¹, S. Devlin^1,1, D. Sarasohn¹, L. Gilbert¹, A. Khorana³, S. Mantha¹
Abstract Number: OC 68.3

The Link between Inflammation, Coagulation and Endothelium Damage in COVID-19: Evidence from an Exploratory Cross-sectional Study

M.R. Peralta¹, V. Muczynski², J. McVey³, B. Gration⁴, P. Lane¹, L. Pagala¹, A. Riddell¹, S. Baghani⁵, B. Agarwal⁶, H. Avula⁷, K. Gomez¹, A. Davenport⁸, A. Drebes¹, S. Taybali⁴, K. Tushar⁹, D. Aggarwal⁴, C. Diaz Garcia¹, A. Nair¹⁰, D. Martin¹¹, P. Chowdary¹
Abstract Number: LB 01.4

The Management of SubSegmental Pulmonary Embolism without Anticoagulation

G. Le Gal¹, M. Kovacs², F. Couturaud³, A. Hirsch⁴, M. Huisman⁵, E. Klok⁵, N. Kraaijpoel⁶, M. Righini⁷, M. Rodger⁴, P.-M. Roy⁸, O. Sanchez⁹, J. Schmidt¹0, S. Schulman¹¹, S. Shivakumar¹², A. Trinh-Duc¹³, U. Vinsonneau¹⁴, P. Wells¹, C. Wu¹⁵, E. Yeo¹⁶, M. Carrier¹
Abstract Number: PB0727

The Paradoxal Association beetween Congenital FVII Deficiency and Thromboembolism

I. krichen¹, N. Moussa², Y. Elloumi¹, F. Megdich¹, W. Fekih², Y. Kammoun¹, S. Kammoun², C. Kallel¹
Abstract Number: PB0575

The Potential Benefits of Physical Exercises for Reducing Pain in Adult Haemophilic Arthropathy Patients: A Meta-analysis of Randomized Controlled Trials

B.P. Putra¹, F.N. Putra²
Abstract Number: LPB0085

The Predominant Role of Arrestin3 in General GPCR Desensitization in Platelets

P.K. Chaudhary¹, S. Kim¹, S. Kim¹
Abstract Number: PB0327

The Prevalence of Gene Polymorphism of the Cytochrome P-450 and VKORC1 System among the Indigenous Population of the Arctic

N. Vorobyeva^1,2, A. Vorobyeva²
Abstract Number: OC 71.3

The Procoagulant and Fibrinolytic Balance of Microvesicles Predicts Mortality in Septic Shock Patients

R. Lacroix^1,2, C. Judicone³, K. Harti Souab², A. Loundou⁴, T. Bouriche³, S. Cointe^1,2, L. Vallier¹, A. Bonifay¹, E. Abdili², L. Arnaud², S. Robert¹, P. Poncelet³, C. Grosdidier², P. Morange^1,2, J.-C. Gris⁵, J.-Y. Lefrant⁵, E. Cochery-Nouvellon⁵, M. Leone², J. Albanese², F. Dignat-George^1,2
Abstract Number: OC 50.4

The Prognostic Value of ADAMTS13 and von Willebrand Factor in COVID-19 Patients: A Prospective Study by Care Setting

G.L. Tiscia¹, G. Favuzzi¹, A. De Laurenzo¹, F. Cappucci¹, L. Fischetti¹, E. Chinni¹, P. Vergura¹, G. Miscio¹, L. di Mauro¹, D. Colaizzo¹, E. Grandone¹
Abstract Number: OC 23.3

The Prognostic Value of Symptoms and Performance Status in Ambulatory Cancer Patients and Unsuspected Pulmonary Embolism: Analysis of an International, Prospective, Observational Cohort Study

A. Maraveyas^1,2, N. Kraaijpoel³, B. Georgios¹, C. Huang², I. Mahe⁴, L. Bertoletti⁵, A. Bartels-Rutten⁶, J. Beyer-Westendorf⁷, J. Constans⁸, D. Iosub⁹, F. Couturaud¹⁰, A. Munoz¹¹, M. Biosca¹², T. Lerede¹³, N. Van Es³, M. Di Nisio¹⁴
Abstract Number: PB0996

The Proteasome Inhibitor, Bortezomib Induces Apoptosis and Activation in Gel Filtered Human Platelets

H. Ghansah¹, I. Beke Debreceni², G. Szabó², J. Kappelmayer²
Abstract Number: OC 19.3

The R543L Protein Altering Variant in the FII Gene (F2) Is a Major Determinant of Coagulation Potential in Mexican Americans

T. Howard¹, M. Almeida¹, V. Diego¹, S. Jhaveri¹, H. Nguyen¹, J. Peralta¹, J. Curran¹, S. Kumar¹, B. Luu², J. Powell³, H. Meade⁴, R. Rajalingam⁵, M. Escobar⁶, D. Lehman⁷, R. DeFronzo⁷, L. Almasy⁸, S. Williams-Blangero¹, R. Duggirala¹, J. Blangero¹
Abstract Number: PB0338

The Red Blood Cell Paradox in Viscoelastic Coagulation Tests – Hemoglobin Concentration as a Confounder for Test Reliability?

I. Pekrul^1,2, S. Adamowicz¹, A. Giebl³, E. Kilger¹, M. Spannagl², P. Möhnle^2,1
Abstract Number: PB0050

The Relationship of 4 Factor PCC or Plasma to INR and Factor Levels: An Exploratory Analysis of 2 Clinical Trials

C. Hood¹, P. Bajcic¹, B. Goldstein¹, J. Goldstein², T. Milling³, M. Refaai⁴, R. Sarode⁵
Abstract Number: PB1109

The RIETE Score: A Useful Screening Tool for Occult Malignancy in VTE and STP?

D. McBriar¹, B. Jacob², G. Benson¹
Abstract Number: LPB0064

The Role of Activated Thrombin Activatable Fibrinolysis Inhibitor on Thrombus Stability in Venous Thromboembolism

J. Chessum^1,2, S. Shaya^1,2, S. Cerroni^2,3, D. Rajab¹, J. Zhou², J.C.M. Meijers^4,5, J. Weitz^1,2,3,6, P. Gross^1,2,3, P. Kim^1,2,3
Abstract Number: OC 34.2

The Role of Acute-phase Circulating miRNAs in Modulating Clinical Outcome in Patients with Venous Thromboembolism

V. Ten Cate^1,2, S. Rapp¹, A. Schulz¹, T. Koeck^1,3, J.H. Prochaska^1,2,3, A. Pallares Robles², K. Jurk², M. Panova-Noeva^1,2, S.-O. Tröbs^1,3, C. Espinola-Klein⁴, M. Halank⁵, H.-J. Seyfarth⁶, S.V. Konstantinides^7,8, T. Münzel^4,3,7, K.J. Lackner^9,3, M.A. Andrade-Navarro¹⁰, P.S. Wild^1,2,3
Abstract Number: PB0275

The Role of D-dimer in Prognosis of Patients with Pulmonary Thrombembolism: Some Aspects for COVID-19

M. Bosevski¹, G. Krstevski¹, E. Dodic², K. Kapsarov³, N. Petkovic⁴, National Registry on Venous Thrombembolism
Abstract Number: PB0569

The Role of Familial Mediterranean Fever in Hemophilia: Should We Tested?

S. Kirkiz¹, Z. KAYA¹, S. Gönen¹, Ü. Koçak¹
Abstract Number: PO192

The Role of Hydroxychloroquine in a Secondary Prevention of Recurrent Thrombosis in Patient with Thrombophilia and Antiphospholipid Syndrome. A Case Report

A. Movsisyan¹, I. Karapetyan², A. Harutyunyan², H. Grigoryan¹, L. Hambardzumyan², J. Simonyan², N. Sargsyan^1,2, G. Tamamyan^1,2, S. Danelyan¹, L. Sahakyan¹, H. Khachatryan^1,2
Abstract Number: PB0956

The Role of Matrix-metalloproteinase 9 in Bone Marrow Remodeling after Total Body Irradiation and Hematopoietic Stem Cell Transplantation

K. Mott¹, D. Semeniak¹, H. Schulze¹
Abstract Number: PB1039

The Role of Nitric Oxide and Cationic Groups in Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent

J. Miklosz¹, B. Kalaska¹, P. Podlasz², M. Chmielewska-Krzesinska², M. Zajaczkowski³, A. Kosinski³, D. Pawlak¹, A. Mogielnicki¹
Abstract Number: PB1020

The Role of Platelet CLEC-2 and GPVI in Rhabdomyolysis-induced Acute Kidney Injury

S. Oishi¹, N. Tsukiji², S. Otake², N. Oishi³, T. Sasaki², T. Shirai², Y. Yoshikawa², K. Takano², H. Shinmori⁴, T. Inukai⁵, T. Kondo³, K. Suzuki-Inoue²
Abstract Number: OC 07.2

The Role of Point-of-Care Musculoskeletal Ultrasound for Routine Joint Evaluation and Management Considerations in Hemophilia Clinic

N. Gallastegui¹, R.F.W. Barnes¹, C. Hanacek¹, R. Kruse-Jarres², B.U.K. Steiner², D.V. Quon³, C. Bailey³, A. von Drygalski^1,4
Abstract Number: PB1089

The Role of Primary Thromboprophylaxis in People with Cancer: A Systematic Review and Meta-analysis

F.A. Dewar¹, K.M. Musgrave¹, J. Simpson¹, J. Hanley²
Abstract Number: LPB0033

The Role of RAP1 Signaling in Platelet-coagulation Interplay

A. Ballard¹, D. Adalsteinsson², E. O’Shaughnessy³, D. Paul¹, R. Lee¹, W. Bergmeier¹
Abstract Number: PB0968

The Role of Septins in Platelet Structure and Function

O.V. Kim¹, O. Vagin², R.I. Litvinov¹, J.W. Weisel¹
Abstract Number: PB0007

The Role of TEC Family Kinases in oxLDL-mediated Platelet Activity in vitro and Platelet and Endothelial Dysfunction in vivo

T. Kohs¹, T. Zheng¹, I. Parra-Izquierdo¹, S. Olson¹, A. Xie¹, J. Hodovan¹, M. Muller¹, C. McArthur¹, J. Johnson¹, M. Wallisch¹, C. Lorentz¹, N. Verbout¹, P. Kievit¹, M. Larson², J. Aslan¹, C. Puy¹, J. Lindner¹, O. McCarty¹, J. Shatzel¹
Abstract Number: OC 41.4

The Role of the Thrombin/PAR Axis in the Anti-tumor CD8+ T Cell Response Following Immune Checkpoint Inhibition Therapy

R. Cantrell^1,2,3, L. Rosenfeldt³, B.K. Sharma³, B. Gourley³, A. Revenko⁴, B. Monia⁴, J. Palumbo³
Abstract Number: PB0250

The Role of Thromboelastography and Follow-up of Fibrinolysis in Evaluating the Course of the Disease, Treatment Response, and Outcome of Pediatric Patients with COVID-19

T. Hilkay Karapınar¹, E. Böncüoğlu¹, Y. Oymak¹, E. Kıymet¹, Ö. Tüfekçi², A. Akaslan Kara¹, K. Ötiken Arıkan¹, Ş. Şahinkaya¹, T. Çelik¹, S.N. Bayram¹, İ. Devrim¹, H. Ören²
Abstract Number: PO119

The Role of Thromboelastography in Search for Drug-candidates

D. Lipatov¹, V. Korunas¹, K. Enikeeva¹, R. Kamilova¹, L. Bashirova¹, I. Bashirov¹, A. Samorodov¹
Abstract Number: PB1104

The Role of Thrombophilia in Asparaginase Related Venous Thromboembolism in Pediatric and Young Adult Patients Affected by Acute Lymphoblastic Leukemia

A. Serrao¹, G.M. Assanto¹, C. Santoro¹, S. Bianchi¹, S. Olivieri², M. Canichella¹, A.M. Testi¹, A. Chistolini¹
Abstract Number: PB1165

The Role of Thrombophilia in Deep Vein Thrombosis of Unusual Sites

I. Chabchoub¹, R. Ben Salah¹, F. Megdiche², C. Kallel², Z. Bahloul¹
Abstract Number: PB1043

The Role of Transforming Growth Factor ß1 (TGFß1) and Fibrinogen in the Induction of Adhesive Properties of Vascular Endothelium (HUVECS) and the Spread of Acute Lymphoblastic Leukemia (ALL)

V. Barilka¹, V. Matlan¹, S. Prymak¹, O. Shalay¹
Abstract Number: OC 38.1

The Role of VWF/FVIII Association in Anti-FVIII Immune Responses in Hemophilia A Mice

Y. Cai^1,2, W. Jing², J.A. Schroeder^1,2, Q. Shi^1,2,3,4
Abstract Number: PB1196

The Roles of Individual and Neighborhood Income on Regional and Racial Differences in Risk of Venous Thromboembolism in the United States: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS)

J. Munger¹, K. Wilkinson², I. Koh², L. Long³, G. Lovasi⁴, L. McClure⁴, J. Brown⁴, G. Howard³, V. Howard³, T. Plante^1,5, M. Cushman^2,5, N. Zakai^2,5
Abstract Number: PB0547

The Safety of Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Perisurgical Settings

J. Mahlangu¹, M. Escobar², M. Callaghan³, J. Ducore⁴, P. De Moerloose⁵, C. Hermans⁶, G. Castaman⁷, J.-F. Schved⁸, J. Journeycake⁹, C. Leissinger¹⁰, J. Luck¹¹, D. Quon¹¹, M. Recht¹², R. Sidonio Jr¹³, A. Srivastava¹⁴, M. Wang¹⁵, G. Young¹⁶, D. Bonzo¹⁷, N. Chambron¹⁸, C. Kessler¹⁹
Abstract Number: PB0829

The Spectrum of Immune Thrombocytopenia with COVID-19 Infection

I. Muhsen¹, J. Petkova¹, L. Rice¹
Abstract Number: PB0128

The Thickness of Fibrin Fibers is Associated with High Fibrin Clot Visco-elasticity in Carcinomatosis Patients

M. Ullah¹, S. Mirshahi^2,1, I. Aldybiat¹, G. Contant², M. Pocard¹, J. Soria¹, M. Mirshahi¹
Abstract Number: OC 58.3

The Tumor Promoting Activity of Osteopontin Is Solely Dependent on its Cleavage by Thrombin

S. Peraramelli¹, Q. Zhou¹, Q. Zhou¹, B. Wanko¹, T.H. Leung², S. Mizuno³, M. Ito⁴, T. Myles¹, T.M. Stulnig⁵, J. Morser¹, L.L. Leung¹
Abstract Number: PB1123

The Use of DOACS in Catheter Related Thrombosis in Cancer

U. Faruqi¹, G. Bahra¹, P.-L. Luo¹, Z. Mahir¹, A. Danaee¹
Abstract Number: PB0431

The Use of Emicizumab for Acquired Hemophilia A at US Hemophilia Treatment Centers

J. Poston¹, R. Kruse-Jarres²
Abstract Number: PB1056

The Utility of the Dilute Prothrombin Time Assay in the Diagnosis of Antiphospholipid Syndrome

T. Storozuk¹, G. Wool¹
Abstract Number: PB0841

The Value of a Rapid, On-demand ADAMTS13 Activity Assay for the Diagnosis of Thrombotic Thrombocytopenic Purpura

A. White¹, R. Martin¹, K. Sew², A. Stucke³, R. Cook¹
Abstract Number: PB0944

The von Willebrand Disease-Woman (VWD-Woman) Trial: A Pilot Study Comparing Recombinant von Willebrand Factor (rVWF) plus Tranexamic Acid (TA) vs. rVWF Alone in the Prevention of Postpartum Hemorrhage in Women with von Willebrand Disease

N. Machin¹, S. Caritis^1,2, C. Seaman^1,3, M. Brooks¹, D. Vehec^1,3, M. Rode^1,3, D. Ivanco^1,3, D. Fischer², D. Zowacki², M. Ragni^1,3
Abstract Number: LB 02.1

The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia A

C. Ay¹, U. Derhaschnig², B. Jilma², C. Schoergenhofer², K. Kovacevic², P. Quehenberger³, P. Jilma³, J.C. Gilbert⁴, S. Zhu⁴, D. Kraemmer¹, A. Iorio⁵, I. Pabinger¹
Abstract Number: PB0661

The World Federation of Hemophilia Gene Therapy Registry

B.A. Konkle^1,2, D. Coffin³, M. Naccache², C. Clark⁴, L.A. George⁵, A. Iorio⁶, W. Miesbach⁷, D. Noone⁸, F. Peyvandi^9,10, S.W. Pipe¹¹, M. Recht¹², M. Skinner¹³, L.A. Valentino¹⁴, J.N. Mahlangu^15,16, G.F. Pierce²
Abstract Number: OC 48.3

Therapeutic Knockdown of Plasminogen with siRNA in Hemophilia A and von Willebrand disease Mouse Models

P. Batty¹, A. Strilchuk², K. Nesbitt¹, A. Yong², D. Lillicrap¹, C. Kastrup²
Abstract Number: PB0818

Therapeutic Landscape in Primary Immune Thrombocytopenia (ITP) over the Last Three Decades in the United Kingdom (UK Adult Primary ITP Registry Project)

P. Raheja¹, H. Miah¹, A. Miah¹, N. Cooper², M. Scully³, T. Biss⁴, S. Chattree⁵, D. Allsup⁶, G. Evans⁷, S. Pavord⁸, G. Matthias⁹, C. Bagot¹⁰, Q. Hill¹¹, C. Bradbury¹², V. Martlew¹³, S. Johns¹⁴, L. Taylor¹, A. Newland¹, D. Provan¹, V. McDonald¹, On behalf of the United Kingdom adult primary ITP registry
Abstract Number: PB0403

Thermal Shift Assay to Probe Melting of Thrombin, Fibrinogen, Fibrin Monomer and Fibrin: Gly-Pro-Arg-Pro Induces a Fibrin Monomer-like State in Fibrinogen

J. Crossen¹, S. Diamond¹
Abstract Number: PB0846

Thirty-five Years of Follow up of a Patient with Congenital Thrombotic Thrombocytopenic Purpura

M. de Oliveira¹, C. Casais¹, C. Gonçalves¹, E. Cruz¹, M. Coutinho¹, M. Pereira¹, J. Coutinho¹, S. Morais¹
Abstract Number: OC 12.2

Three Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-associated Thrombosis (CAT)

K. Sanfilippo^1,2, S. Luo^1,2, A. Khorana³, B. Gage¹
Abstract Number: PB0307

Thrombin Generation (TG) Reveals Underlying Hypercoagulable Process in COVID-19 Patients Despite Low Molecular Weight Heparin (LMWH) Therapy

A. Scazziota^1,2, S. Pons¹, M.d.L. Herrera¹, S. Aguirre¹, V. Monserrat¹
Abstract Number: OC 18.4

Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements: A Prospective Multicenter Cross-sectional Study

T. Meihandoest¹, J.-D. Studt², A. Mendez³, L. Alberio⁴, P. Fontana⁵, W.A. Wuillemin⁶, A. Schmidt⁷, L. Graf⁸, B. Gerber⁹, G.M. Maeder¹, C. Bovet¹, T.C. Sauter¹⁰, M. Nagler¹
Abstract Number: PB0105

Thrombin Generation Assay in Crohn Disease

H. Ben Youssef¹, H. Baccouche¹, S. Meriem¹, C. Aya¹, F. Monia¹, J. Boubaker¹, N. Ben Romdhane¹
Abstract Number: PB0465

Thrombin Generation by Genesia in Patients with Haemophilia A and Inhibitors during Immune Tolerance Induction

T. Szanto^1,2, E. Lehtinen¹, M. Lemponen², R. Lassila^1,2
Abstract Number: PB0543

Thrombin Generation Capacity of Patients with Severe Haemophilia Receiving Prophylaxis (HOPE Study)

S. Meunier¹, A. Lienhart¹, M. Trossaert², V. Gay³, C. Berger⁴, B. Tardy⁴, F. Volot⁵, Y. Dargaud⁶
Abstract Number: PB0613

Thrombin Generation in Hemophilia A Patients after Infusion of Recombinant and PlasmadDerived Factor VIII Concentrates

O. Smirnova¹, O. Matvienko¹, V. Burakov¹, V. Soldatenkov¹, K. Komissarov¹, L. Papayan¹
Abstract Number: PB1157

Thrombin Generation in Newly Diagnosed Multiple Myeloma

D. Velasco-Rodríguez¹, I. Martínez-Alfonzo¹, A. Velasco-Valdazo², R. Vidal Laso¹, C. Díaz¹, N. Revilla³, A. García-Raso¹, J.M. Alonso-Domínguez¹, S. Martín-Herrero¹, E. Askari¹, E. Prieto¹, M.J. Blanchard³, F.J. López-Jiménez³, P. Llamas-Sillero^1,2
Abstract Number: PB0124

Thrombin Generation is Affected by Freezing Independent of Storage Temperature

M. Ninivaggi¹, A. Carlo², R. de Laat - Kremers¹, B. de Laat¹
Abstract Number: PB0156

Thrombin Generation Kinetics, Neutrophil Extracellular Traps, and von Willebrand Factor in COVID-19 Associated Coagulopathy: A Pilot Study

T. MacArthur¹, J. Goswami¹, M. Sridharan², J. Tange², A. Kirmse¹, K. Lundell¹, M. Auton², T. Chon³, R. Hurt³, B. Salonen³, R. Ganesh³, J.-F. Dong⁴, R. Kozar⁵, S. Heller¹, E. Loomis¹, A. Johnstone⁶, K. Bailey⁷, G. Spears⁷, M. Park¹
Abstract Number: OC 14.4

Thrombin Generation Rescued in Hemophilia A by Low-normal Levels of FV Is Confirmed to Be Partially due to Substrate Competition

M. Stobb¹, A. Fogelson², S. Sindi³, K. Leiderman⁴, K. Neeves⁵, D. Monroe⁶
Abstract Number: PB1291

Thrombin Generation Test and Use of Combined Oral Contraceptive

M. Sousa¹, R.C. Figueiredo Duarte¹, M.d.G. Carvalho¹, I.d.F. Oliveira Silva¹, D. Serenini¹, L. Dusse¹
Abstract Number: OC 77.4

Thrombin Mediated Activation of Protease Activated Receptor 1 Contributes to Doxorubicin Induced Cardiac Injury

S. Grover¹, J. Posma^1,2, J. Griffin³, N. Mackman¹, S. Antoniak¹
Abstract Number: OC 27.1

Thrombin Spatial Distribution Determines the Contribution of Activated Protein C to Endogenous Anti-coagulant Activity during Hemostasis and Thrombosis in vivo

T. Marar^1,2, C. Matzko², J. Wu², C. Esmon³, T. Sinno², L. Brass², M. Tomaiuolo², T. Stalker^1,2
Abstract Number: LPB0144

Thrombocytopenia in Pregnancy: Identification and Management at a Reference Centre in Pakistan

M. Borhany¹, M. Abid¹, S. Zafar¹, T. Shamsi¹
Abstract Number: PB0419

Thromboelastography for the Evaluation and Management of Patients with Traumatic Brain Injury

J. Dias¹, J. Hartmann¹, J. Cannon²
Abstract Number: PB0669

Thromboelastography to Monitor Periprocedural Hemostasis in Advanced Liver Disease: A Systematic Review and Meta-analysis

J. Hartmann¹, J. Dias¹, E. Pivalizza², G. Garcia-Tsao³
Abstract Number: PB1094

Thromboembolic and Bleeding Complications fFowing Surgery among Patients with Ovarian Cancer – A Single Centre Retrospective Cohort Study

H.M. Wiegers¹, M. Schaafsma¹, H. Zelisse¹, N. van Es¹, S. Middeldorp², C.H. Mom¹
Abstract Number: PB1284

Thromboembolic disease (VTE) and Inmune Trombocytopenia (ITP): A Case Report

M. R. Lopez¹, E. Lopez Ansoar¹, A. Nieto Vazquez¹, C. Albo Lopez¹
Abstract Number: PB0721

Thromboembolic Disease in Severe Factor V (FV) Deficiency: A Case Report: “Anticoagulating the Anticoagulable”

M. R. Lopez¹, E. Lopez Ansoar¹, A. Nieto Vazquez¹, C. Albo Lopez¹
Abstract Number: PB0292

Thromboembolism and Coagulopathy in COVID-19: A Review of Quality Indicators at Sunnybrook Health Sciences Centre

A. Suleman¹, S. Carlin², W. Geerts²
Abstract Number: PB1190

Thromboembolism is Prevalent and Adversely Affects Overall Survival in Adults with Hemophagocytic Lymphohistiocytosis

J. Croden¹, L. Bilston², J. Grossman³, H. Sun⁴
Abstract Number: PB1007

Thrombogenic Potential in Patients Undergoing Hemodialysis Using Central Venous Catheter and Arteriovenous Fistula

M. Dumont Cunha¹, M. Henrique Fernandes Ottoni¹, M. Araújo Figueiredo¹, T. Coaglio Lucas¹
Abstract Number: PB0422

Thrombolysis and Anti-cancer Activity of Koji-Natto (Kojikinase)

H. Sumi¹, T. Mitsuo², C. Yatagai¹
Abstract Number: PB0424

Thrombolytic Activity of Pearl-like Tempeh

H. Sumi¹, Y. Yanagisawa², S. Naito¹, C. Yatagai¹
Abstract Number: PO166

Thrombophilia and Thromboembolic Venous Disease in Southern Tunisia

I. Chabchoub¹, R. Ben Salah¹, F. Megdiche², C. Kallel², Z. Bahloul¹
Abstract Number: PB1293

Thromboprophylaxis in High-risk Obese Pregnant Women: How Much Is Enough?

A. Rodríguez Alén¹, M. De la Torre De la Paz¹, N. Rollón Simón¹, S. Daza Pozo¹, M.O Abío Calvete¹, L. Parrilla Navamuel¹, G. Figaredo García-Mina¹, M. Jiménez Sánchez², O. Rodríguez Gómez², A. García López², S. Moreno Ramírez¹, K.G. Albiño Salazar¹, J. Cuesta Tovar¹
Abstract Number: PB0237

Thrombosis and Bleeding in Critically Ill COVID-19 Patients at Higher than Prophylactic Dose of Heparins

A. Mavri¹, M. Lukić², M. Mavrič², N. Šoštarič², D. Zupančič²
Abstract Number: PO184

Thrombosis in Elderly: Watch out Antipsychotic Agents!

M. Mrouki¹, H. Hamitou¹, P. Tissot¹, I. Lusamvuku¹, S. Maillard¹, C. Bonhoure¹
Abstract Number: PB1135

Thrombotic and Hemorrhagic Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

E. Gonzalez Gomez¹, N. Fernandez Mosteirin¹, M. Moreno Carbonell¹, S.F. Pinzon Mariño¹, A. Garcia Ortego¹, A. Gomez Martinez¹, C.F. Hernandez Mata¹, S. Martin Consuegra¹, M. Civeira Marin¹, A. Lopez Peña¹, C. Rodriguez Lefler¹, M.S. Ordas Miguelez¹, M.d.M. Herrero Gutierrez¹, P.E. Lopez Gomez¹, M.P. Delgado Beltran¹, J.M. Calvo Villas¹
Abstract Number: LPB0123

Thrombotic Complications in a Cohort of Children with Myeloproliferative Neoplasms

N. Kucine¹, V. Vanderpoel², K. Shimano²
Abstract Number: OC 40.1

Thrombotic Complications in Pediatric Patients Hospitalized with COVID-19 Disease or Associated Multisystem Inflammatory Syndrome in Children (MIS-C)

M. Torres¹, J. Tilley¹, M. Trang¹, A. Schenk¹
Abstract Number: PB0147

Thrombotic Events in COVID-19 Are Associated with a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity

C. Clark¹, B. Jukema¹, A. Barendrecht¹, J. Spanjaard², N. Jorritsma², S. Smits¹, S. de Maat¹, C. Seinen¹, S. Sebastian¹, A. Koekman¹, A. van Wesel¹, H. van Goor³, R. Spijkerman^2,4, S. Bongers^2,5, E. van der Vries¹, S. Nierkens², M. Boes², L. Koenderman^2,4, K. Kaasjager³, C. Maas¹
Abstract Number: PB0881

Thrombotic Microangiopathies (TMA): In vivo Evidence for Platelet Activation and Endothelial Cell Injury, and Potential for Therapeutic Intervention with Defibrotide

S. Elhadad¹, S. Subrahmanian², J. Ahamed², J. Laurence¹
Abstract Number: PB0163

Thrombotic Microangiopathy in Two Patient with Covid 19 Disease

P. Bradacova¹, L. Slavik², J. Ullrychova¹, J. Ulehlova², J. Prochazkova², A. Hlusi²
Abstract Number: PB0212

Thrombotic Risk of Hospitalized Patients with COVID-19 and a Co-infection

I. Akpan¹, L. Van Doren¹, J. Travers², K. Runcie¹, A. Wei¹, J. Cogan¹, Y. Pumpalova¹, D. Diuguid¹, A. Eisenberger¹, R. Francis¹
Abstract Number: PB0815

Time Course of Response to Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor for the Treatment of Immune Thrombocytopenia (ITP)

M. Sholzberg¹, D. Arnold², D. Liles³, R. Numerof⁴, M. Boxer⁵
Abstract Number: PB0142

Time Course of the Development of Immunothrombosis during COVID-19 Hospitalization

J. Oliveira¹, G. Vieira-Damiani^1,2, G. Locachevic³, J. Mariolano³, K. Soares³, A. Santos¹, B. Jacintho¹, C. Vaz¹, G. Mesquita¹, E. Paula^4,5, F. Orsi^4,3
Abstract Number: PB0560

Time from the Inhibitor Detection to the Start of Immune Tolerance Induction and the Outcome of Immune Tolerance Induction: Results from the Brazilian Immune Tolerance (BrazIT) Study

R.M. Camelo^1,2, M.M. Dias¹, C. Caram-Deelder^2,3, S. Gouw⁴, L.P. de Magalhaes¹, L.W. Zuccherato¹, L.L. Jardim^1,2, J. van der Bom^2,3, S.M. Rezende¹
Abstract Number: PB0553

Tissue Factor Pathway Inhibitor (TFPI) Levels and Bleeding Risk in Patients with Severe Hemophilia A or B

B. Tardy-Poncet^1,2,3, A. Montmartin³, F. Genre-Volot⁴, H. Chambost⁵, E. De Maistre⁴, P. Morange⁵, L. Ardillon⁶, Y. Dargaud⁷, A. Lienhart⁷, P. Nguyen⁸, B. Frotscher⁹, B. Wibaut¹⁰, C. Derory², M. Delolme¹, B. Tardy²
Abstract Number: PB0153

Tissue Factor-stimulated Plasma Thrombin Generation Is Enhanced in Hospitalised Patients with COVID-19 Despite Pharmacological Thromboprophylaxis

S. Kelliher^1,2, L. Weiss^2,3, S. Cullivan^4,2, E. O'Rouke¹, C. Murphy^2,5, S. Toolan¹, A. Lennon¹, P.B Szklanna^2,3, S. Comer^2,3, H. Macleod², S. Gaine^4,6, K. O'Reilly^4,6, B. McCullagh^4,6, J. Stack^7,6, P.WG Mallon^6,8,9, A. Cotter^6,9,10, P.B Maguire^2,3,11, F. Ní Áinle^1,2,6,12,13, B. Kevane^1,2,6,13
Abstract Number: PB0008

Tissue Inhibitor of Metalloproteinases-1 (TIMP1) is Related to Residual Thromboxane Dependent Platelet Activation in Patients with Type 2 Diabetes Mellitus Receiving Low Dose Aspirin

P. Simeone¹, R. Tripaldi¹, R. Liani¹, S. Ciotti¹, V. Cavalca², M. Camera², E. Tremoli², F. Santilli¹
Abstract Number: LPB0005

Tissue-engineered Human Arteries Replicate Primary and Secondary Haemostatic Functions Seen in vivo: A Replacement for Mouse Arterial Thrombosis Models?

J. Ranjbar¹, Y. Yang¹, A. Harper¹
Abstract Number: PB0075

Titanium Compounds Bind and Activate Factor XII and Prekallikrein

M. Litvak¹, A. Matafonov¹, A. Shamanaev¹, A. Kobrin¹, A. Gruber^2,3, O.J. McCarty², D. Gailani¹
Abstract Number: PB0441

To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report

R. Khalife¹, A. Aw¹, L. Duffett¹, O. Radhwi¹, L. Lacasse¹, L. Huebsch¹, M. Bowman², P. James², A. Tinmouth¹
Abstract Number: LB 02.2

Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

A. Greinacher¹, K. Selleng¹, J. Wesche¹, S. Handtke¹, R. Palankar¹, U. Völker², T. Thiele¹, F. Siegerist³, N. Endlich³, C. Rangaswamy⁴, R.K Mailer⁴, H. Englert⁴, M. Frye⁴, T. Warkentin⁵, T. Renne⁴
Abstract Number: PB0410

Tranexamic acid for Hyperacute Primary Intracerebral Haemorrhage (TICH-3): Protocol for a Multinational Phase 3 Placebo-controlled Randomised Trial

M. Desborough^1,2, R. Al-Shahi Salman³, T. Coats⁴, R. Dineen⁵, T. England⁶, D. Havard⁵, T. Hepburn⁷, S. Hodgson⁵, M. James⁶, A. Montgomery⁶, C. Rick⁶, I. Roberts⁸, T. Robinson⁴, C. Roffe⁹, D. Werring¹⁰, P. Bath⁵, N. Sprigg⁵
Abstract Number: PB0412

Tranexamic Acid to Reduce Bleeding in Patients Treated with Non-Vitamin K Oral Anticoagulants Undergoing Dental Extraction: The EXTRACT-NOAC Randomized Clinical Trial

A. Ockerman¹, I. Miclotte¹, M. Vanhaverbeke², T. Vanassche², A. Belmans¹, J. Vanhove³, J. Meyns⁴, N. Nadjmi^5,6, G. Van Hemelen⁶, P. Winderickx⁶, R. Jacobs^1,7, C. Politis², P. Verhamme².
Abstract Number: OC 31.1

Transcription Factor RUNX1 Regulates Factor XIIIA Subunit (F13A1) Expression in Platelets and Megakaryocytic Cells: Decreased Platelet F13A1 Expression and Clot Retraction in RUNX1 Haplodeficiency

F. Del Carpio-Cano¹, N. Songdej², G. Mao³, J. Wurtzel⁴, L. Goldfinger⁴, M.P. Lambert⁵, AK. Rao⁶
Abstract Number: OC 13.4

Transcriptional Analysis of the Response to Stimulation in ECFCs Derived from Type 1 VWD Patients

R. Kloosterman¹, M. Zago-Schmitt¹, J. Grabell², L. Thibeault³, M. Bowman², P.D.A. Lima⁴, K. Tyryshkin¹, C.C.T. Hindmarch⁴, N. Renwick¹, P. James²
Abstract Number: OC 29.4

Transcriptomics and Proteomics to Study the Effect of Hyperactive SRC Kinase during Megakaryopoiesis

L. De Kock¹, F. Ver Donck¹, C. Thys¹, C. Van Geet¹, K. Freson¹
Abstract Number: PB1290

Transferability of the ETP-based APC Resistance Assay on the ST Genesia System

L. Morimont^1,2, M. Didembourg¹, J.-M. Dogné¹, A. Carlo³, J. Douxfils^1,2
Abstract Number: PB0304

Transient Lupus Anticoagulant Presence in COVID-19 Pneumonia, a Probably Epiphenomenon

M. Martinuzzo^1,2, M.S. López^1,2, I. Carboni Bisso³, I. Huespe^4,5, M. Las Heras³, E. Prado³, V. Privitera⁶, M. Garbarini^3,6, L. Barrera^7,2, J. Sinner³
Abstract Number: OC 14.1

Transplacental Delivery of Maternal FVIII for Induction of FVIII-specific Immune Tolerance

A. Mimoun^1,2,3, M. Bou Jaoudeh^1,2,3, I. Peyron^4,5, V. Daventure^1,2,3, S. Delignat^1,2,3, A. Reyes Ruiz^1,2,3, O. Christophe^4,5, P. Lenting^4,5, C. Denis^4,5, S. Lacroix-Desmazes^1,2,3
Abstract Number: OC 48.2

Transplacental Delivery of Recombinant Fc-fused Factor VIII (rFVIIIFc) in FVIII-deficient Mice

A. Reyes-Ruiz^1,1, S. Delignat¹, A. Mimoun¹, A. Azam¹, D. Lillicrap², S. Lacroix-Desmazes¹
Abstract Number: PO112

Treatment of Advanced Atherosclerotic Plaque with Neovascularization Using B-mode Ultrasound-guided HDL-loaded Microbubbles-mediated Low Level Focused Electrohydraulic Shock Wave Sonoporation Therapy and Cholesterol Diet Withdrawal

H. Mehrad^1,2, A. Foletti^3,2
Abstract Number: PB1116

Treatment of Cancer-associated Thrombosis with Six Months of Prophylactic-dose Enoxaparin after Initial Full-dose Anticoagulation: A Pilot Study

J. Popov¹, S. Coelho², M. Carrier³, C. Sperlich⁴, S. Solymoss^5,6, N. Routhier^7,8, S. Shivakumar^9,10, W. Aibibula², S. Kahn^1,2, V. Tagalakis^1,2
Abstract Number: LPB0075

Treatment of Catheter-related Arterial Thrombosis in Children: A 15-year Single Center Experience

O. Crameri¹, M. Rizzi², M. Albisetti¹.
Abstract Number: PB0833

Treatment of Immune Thrombocytopenia (ITP) in the COVID-19 Era: Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor

N. Cooper¹, A. Charania², A. Hart³, C. Ademokun³, R. Numerof⁴
Abstract Number: PB1115

Treatment of Venous Thromboembolism (VTE) Events with Cancer as a Risk Factor in a Teaching Hospital: 2015 – 2020

H. Rowswell¹, T. Nokes¹
Abstract Number: PB0518

Treatment Patterns and Clinical Outcomes among Patients with Hemophilia A Treated with Factor VIII Replacement Therapies and Nonfactor Therapy: An Assessment of US Real-world Data

A. Adeyemi¹, A. Cockerham¹, R. Preblick¹, A. Swenson², J. Dumont¹
Abstract Number: OC 25.1

Trends in Venous Thromboembolism and Death in COVID-19 Positive Patients in 2020

A. Pasha¹, R. Chaudhary¹, L. Padrnos², E. Wysokinska³, R. Pruthi¹, M. Sridharan¹, P. Daniels¹, R. McBane¹, D. Houghton¹
Abstract Number: PB1212

Trombophilia and Other Risk Factors of Cerebral Venous Sinus Thrombosis in 255 Patients

A. Gwozdowska¹, E. Odnoczko², B. Baran², J. Windyga^1,2, A. Gwozdowska, E. Odnoczko, B. Baran, 1,2 J. Windyga
Abstract Number: PO146

TSUBASA Study: An Observational Study of Emicizumab to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

K. Nogami¹, T. Fujii², A. Sawada³, A. Nagao⁴, C. Nagae⁵, N. Suzuki⁶, M. Nojima⁷, D. Nosaka⁸, T. Nakamura⁸, S. Yoshida⁸, K. Amano⁹
Abstract Number: PB0849

TTP during Pregnancy: Acquired or Late-Onset Congenital? A Diagnostic Challenge

S. Demeester¹, N. De Beule¹, C. Orlando¹, A. De Becker¹, K. Jochmans¹
Abstract Number: PB0746

Tumor Cell-induced Platelet Aggregation is Sustained by Platelet Entrapment into the Fibrin Network Formed by Thrombin

I. Tesakov¹, A. Filkova^2,3,4, A. Deputatova⁴, A. Korneichuk⁴, S. Obydennyi^2,3, I. Kireev⁵, M. Panteleev^2,3,4, A. Sveshnikova^2,3,4
Abstract Number: OC 30.2

Tumor Gene Expression Associates with Venous Thromboembolism in Patients with Pancreatic Cancer

F. Bosch^1,2, F. van Dijk², S. Briedé³, J. Groen⁴, R. Hanna-Sawires⁴, F. Klok⁴, H. Kaasjager³, L. Brosens³, I. Molenaar³, B. Bonsing⁴, J. Mieog⁴, M. Besselink², O. Busch², J. Verheij², A. Farina-Sarasqueta², J. Wilmink², M. Bijlsma², H. Versteeg⁴, N. van Es², J.T. Buijs⁴
Abstract Number: PB1140

Tumor Somatic Mutations as Predictors of CDK4/6 Inhibitor Associated Thromboembolism in Women with Metastatic Breast Cancer

M. West¹, R. Thawani^1,1, J. Shatzel¹
Abstract Number: PB0685

Twelve Months of Emicizumab Prophylaxis in a Severe Hemophilia A Man with Inhibitor who Failed Immune Tolerance Induction: Effectiveness, Economic, and Safety Outcomes

R.M. Camelo¹, T.C. de Medeiros², D.G.B. de Albuquerque², N. Dantas-Silva³, J. Álvares-Teodoro⁴
Abstract Number: PB0683

Twelve Months of Emicizumab Prophylaxis in a Woman with Mild Hemophilia A and Inhibitor: Effectiveness, Safety and Economic Outcome

R.M. Camelo¹, E.S. Casaretto², M.D. Castro Tenório², N. Dantas-Silva³, S.S. de Figueiredo², J. Álvares-Teodoro⁴